Trends in prostate cancer incidence between 1996 and 2013 in two Swiss regions by age, grade, and T-stage

Wanner, Miriam; Richard, Aline; Matthes, Katarina L.; Ortelli, Laura; Lorez, Matthias; Korol, Dimitri; Bordoni, Andrea; Rohrmann, Sabine

doi:10.1007/s10552-017-0993-9

Cited by 4 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes towards less PSA screening in Switzerland may have occurred before this recommendation. Our finding concurred with a recent regional Swiss study which reported an increase in incidence of prostate cancer in men aged under 65 years in the canton of Zurich up to 2002 and in canton of Ticino up to 2007, followed by a decline [23]. If this trend were to continue in Switzerland, the incidence of early-stage prostate cancer could decrease.…”

Section: Discussionsupporting

confidence: 92%

Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?

et al. 2019

View full text Add to dashboard Cite

BackgroundScreening for prostate cancer is frequent in high-income countries, including Switzerland. Notably due to overdiagnosis and overtreatment, various organisations have recently recommended against routine screening, potentially having an impact on incidence, mortality, and surgery rates. Our aim was therefore to examine whether secular trends in the incidence and mortality of prostate cancer, and in prostatectomy rates, have recently changed in Switzerland.MethodsWe conducted a population-based trend study in Switzerland from 1998 to 2012. Cases of invasive prostate cancer, deaths from prostate cancer, and prostatectomies were analysed. We calculated changes in age-standardised prostate cancer incidence rates, stratified by tumor stage (early, advanced), prostate cancer-specific mortality, and prostatectomy rates.ResultsThe age-standardised incidence rate of prostate cancer increased greatly in men aged 50–69 years (absolute mean annual change +4.6/100,000, 95% CI: +2.9 to +6.2) between 1998 and 2002, and stabilised afterwards. In men aged ≥ 70 years, the incidence decreased slightly between 1998 and 2002, and more substantially since 2003. The incidence of early tumor stages increased between 1998 and 2002 only in men aged 50–69 years, and then stabilised, while the incidence of advanced stages remained stable across both age strata. The rate of prostatectomy increased markedly until 2002, more so in the 50 to 69 age range than among men aged ≥ 70 years; it leveled off after 2002 in both age strata. Trends in surgery were driven by radical prostatectomy. Since 1998, the annual age-standardised mortality rate of prostate cancer slightly declined in men aged 50–69 years (absolute mean annual change -0.1/100,000, 95% CI: -0.2 to -0.1) and ≥ 70 years (absolute mean annual change -0.5/100,000, 95% CI: -0.7 to -0.3).ConclusionsThe increases in the incidence of early stage prostate cancer and prostatectomy observed in Switzerland among men younger than 70 years have concomitantly leveled off around 2002/2003. Given the decreasing mortality, these trends may reflect recent changes in screening and clinical workup practices, with a possible attenuation of overdiagnosis and overtreatment.

show abstract

Section: Discussionsupporting

confidence: 92%

Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?

et al. 2019

View full text Add to dashboard Cite

show abstract

“…An increase in incidence is supported by data from the French-speaking part of Switzerland for the period from 1974 until at least 1994 (canton of Vaud) [21], and from 1973 until about 2000 (canton of Geneva) [22]. Increasing incidence was also observed in the Italianspeaking part of Switzerland from 1996 until 2007 [12], even though the rates in these regions were considerably lower. The latter study was a comparison of prostate cancer incidence between Zurich and Ticino for the period 1996 to 2013 [12].…”

Section: Comparison With Other Studiesmentioning

confidence: 75%

“…Increasing incidence was also observed in the Italianspeaking part of Switzerland from 1996 until 2007 [12], even though the rates in these regions were considerably lower. The latter study was a comparison of prostate cancer incidence between Zurich and Ticino for the period 1996 to 2013 [12]. A strong increase in incidence from the 1970s or 1980s, up to around 2000-2005 and levelling off afterwards, was reported in other European countries [23,24].…”

Section: Comparison With Other Studiesmentioning

confidence: 90%

“…While for men older than 70 years of age, the turning point from an increasing to a decreasing rate was around 1990, it was later for younger men (after 2000). A steep increase in stage I tumours up to 2011 may be associated with increased PSA screening behaviour in the early 2000s [12]. Furthermore, the coding based on TNM classification of malignant tumours changed in 2010 from version 6 [6] to version 7 [7], with the result that T2a tumours were newly classified as stage I instead of stage II tumours, which may explain the decrease in stage II tumours and the simultaneous increase in stage I tumours.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

37-year incidence and mortality time trends of common cancer types by sex, age, and stage in the canton of Zurich

et al. 2020

Self Cite

View full text Add to dashboard Cite

AIMS OF THE STUDY: The Cancer Registry Zurich, Zug, Schaffhausen and Schwyz is one of the oldest cancer registries in Switzerland, first registering tumours in 1980 for the canton of Zurich. The aim of this study was to analyse trends in incidence and mortality for the most common types of cancer in the canton of Zurich from 1981 to 2017. METHODS: In this analysis of population-based cancer registry data, we included malignant tumours of the breast (ICD10 C50), prostate (C61), colon/rectum (C18-C21), lung (C33-C34), and melanoma (C43), diagnosed between 1981 and 2017. Age-standardised incidence and mortality rates per 100,000 person-years were computed using the 1976 European Standard Population. Incidence and mortality time trends were assessed using joinpoint regression analysis. RESULTS: In men, incidence for prostate cancer and melanoma increased over the study period, while it decreased for colon/rectum and lung cancer. A joinpoint for prostate cancer indicated the start of a decreasing trend in 2002. In women, incidence increased for breast cancer, lung cancer and melanoma; no trend was observed for colon/rectum cancer. Cancer mortality decreased for prostate, colon/rectum and lung cancer in men, with no clear trend for melanoma. In women, mortality decreased for breast cancer, colon/rectum cancer and melanoma, but increased for lung cancer. CONCLUSIONS: The overall increasing incidence trends for prostate and breast cancer, as well as for melanoma, are in line with data from other Western countries. While lung cancer incidence is decreasing in men, it is still on the rise in women. Despite increasing incidence rates, mortality rates are decreasing for all localisations except for lung cancer in women. The opposite direction of incidence and mortality curves is probably mostly due to better and more effective treatment options, as well as earlier detection.

show abstract

“…Before the 1980s, the incidence of prostate cancer in China was less than 1/100,000, and the incidence was extremely low, but after decades of change, the incidence of prostate cancer has now exceeded 5/100,000, and it is skyrocketing, nearly fivefold to the original. Specifically, the incidence of prostate cancer registered in China in 2012 was 9.92/100,000; the sixth highest incidence of malignant neoplasms in men, and in 2018, prostate cancer patients in Asia accounted for 18,100,001 and half of the world's new patients [12,13].…”

Section: Introductionmentioning

confidence: 99%

An Intelligent Decision-Making Support System for the Detection and Staging of Prostate Cancer in Developing Countries

Zhang

Chen

et al. 2020

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Most developing countries face huge challenges in the medical field; scarce medical resources and inadequate medical personnel will affect the development and stability of the society. Therefore, for most developing countries, the development of intelligent medical systems can greatly alleviate the social contradictions arising from this problem. In this study, a new data decision-making intelligent system for prostate cancer based on perceptron neural network is proposed, which mainly makes decisions by associating some relevant disease indicators and combining them with medical images. Through data collection, analysis and integration of medical data, as well as the disease detection and decision-making process, patients are given an auxiliary diagnosis and treatment, so as to solve the problems and social contradictions faced by most developing countries. Through the study of hospitalization information of more than 8,000 prostate patients in three hospitals, about 2,156,528 data items were collected and compiled for experiment purposes. Experimental data shows that when the patient base increases from 200 to 8,000, the accuracy of the machine-assisted diagnostic system will increase from 61% to 87%, and the doctor’s diagnosis rate will be reduced to 81%. From the study, it is concluded that when the patient base reaches a certain number, the diagnostic accuracy of the machine-assisted diagnosis system will exceed the doctor’s expertise. Therefore, intelligent systems can help doctors and medical experts treat patients more effectively.

show abstract

Trends in prostate cancer incidence between 1996 and 2013 in two Swiss regions by age, grade, and T-stage

Cited by 4 publications

References 28 publications

Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?

Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?

37-year incidence and mortality time trends of common cancer types by sex, age, and stage in the canton of Zurich

An Intelligent Decision-Making Support System for the Detection and Staging of Prostate Cancer in Developing Countries

Contact Info

Product

Resources

About